Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Immunome Inc., 3 years.
Immunome Inc.
Director
Ligand Pharmaceuticals Incorporated
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Ligand Pharmaceuticals Incorporated June 5, 202695.3%
-
Ligand Pharmaceuticals Incorporated June 9, 202594.9%
-
Ligand Pharmaceuticals Incorporated June 14, 202496.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −257 | $247.22 | $63,536 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −232 | $248.11 | $57,562 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −697 | $249.53 | $173,922 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −3,405 | $251.62 | $856,766 |
| Jun 5, 2026 | Ligand Pharmaceuticals Incorporated | Grant or award | +836 | — | — |
| Mar 6, 2026 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,161 | $114.15 | $246,678 |
| Mar 6, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,161 | $200.76 | $433,842 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,145 | $66.13 | $141,849 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,145 | $205.45 | $440,690 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,034 | $69.51 | $141,383 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,034 | $205.45 | $417,885 |
| Jun 6, 2025 | Ligand Pharmaceuticals Incorporated | Grant or award | +1,209 | — | — |
| Nov 27, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,406 | $52.30 | $125,834 |
| Nov 27, 2024 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,406 | $123.65 | $297,502 |
| Jun 14, 2024 | Ligand Pharmaceuticals Incorporated | Grant or award | +1,252 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.